CRISPR-Cas9-based target validation for p53-reactivating model compounds

Inactivation of the p53 tumor suppressor by Mdm2 is one of the most frequent events in cancer, so compounds targeting the p53-Mdm2 interaction are promising for cancer therapy. Mechanisms conferring resistance to p53-reactivating compounds are largely unknown. Here we show using CRISPR-Cas9–based ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanzel, Michael, Vischedyk, Jonas B, Gittler, Miriam P, Gremke, Niklas, Seiz, Julia R, Hefter, Mirjam, Noack, Magdalena, Savai, Rajkumar, Mernberger, Marco, Charles, Joël P, Schneikert, Jean, Bretz, Anne Catherine, Nist, Andrea, Stiewe, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910870/
https://www.ncbi.nlm.nih.gov/pubmed/26595461
http://dx.doi.org/10.1038/nchembio.1965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910870/
https://www.ncbi.nlm.nih.gov/pubmed/26595461
http://dx.doi.org/10.1038/nchembio.1965

Ejemplares similares